• Lunai Bioworks’ BioSymetrics unit signed a strategic collaboration and LOI with BrainStorm Therapeutics to discover neurology drug targets.
• Work combines BioSymetrics’ AI target discovery with zebrafish validation, BrainStorm’s human-derived brain organoids to generate partnerable CNS programs.
• Initial focus targets rare genetic epilepsies, Parkinson’s disease; effort integrates BrainStorm’s midbrain organoid model with PPMI dataset analysis.
• Flagship rare epilepsy program received grant funding from the LouLou Foundation to advance targets toward validation and development-stage assets.
• LOI sets a framework to expand into additional indications, aiming to move programs to licensing or other partnering structures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA69603) on May 28, 2026, and is solely responsible for the information contained therein.